It is very uncertain whether the intervention changes infant Mortality at 18 months (very low certainty).
It is very uncertain whether the intervention changes HIV Transmission or Death at 18 months among those whose HIV… (very low certainty).
It is very uncertain whether the intervention changes infants with Grade 3/4 Signs or Symptoms (very low certainty).
It is very uncertain whether the intervention changes infants with Grade 3/4 Laboratory Abnormalities (very low certainty).
An extended NVP regimen administered to infants for 14 weeks probably leads to lower HIV Transmission at 24 months among those uninfected at birth11 compared with sdNVP plus ZDV (1week) (moderate certainty).
It is very uncertain whether the intervention changes infant with Toxicity Events leading to cessation of ZDV (very low certainty).
An extended ZDV/3TC/LPV/r regimen administered to mothers showed no clear difference in HIV transmission at 6 months among those whose HIV diagnostic… compared with an extended ZDV/3TC/ABC administered to mothers (low certainty).
An extended ZDV/3TC/LPV/r regimen administered to mothers showed no clear difference in infant Mortality at 6 months compared with an extended ZDV/3TC/ABC administered to mothers (low certainty).
It is very uncertain whether an extended ZDV/3TC/LPV/r regimen administered to mothers changes HIV Transmission or Death at 6 months among those whose HIV… compared with an extended ZDV/3TC/ABC administered to mothers (very low certainty).
An extended ZDV/3TC/LPV/r regimen administered to mothers showed no clear difference in infants with Grade 3/4 Severe Adverse Events compared with an extended ZDV/3TC/ABC administered to mothers (low certainty).
An extended ZDV/3TC/LPV/r regimen administered to mothers showed no clear difference in maternal Mortality at 6 months compared with an extended ZDV/3TC/ABC administered to mothers (low certainty).
An extended ZDV/3TC/LPV/r regimen administered to mothers showed no clear difference in mothers with any Grade 3/4 Severe Adverse Event compared with an extended ZDV/3TC/ABC administered to mothers (low certainty).
It is very uncertain whether an extended ZDV/3TC/LPV/r regimen administered to mothers changes mothers with Severe Adverse Events Requiring Treatment Modification compared with an extended ZDV/3TC/ABC administered to mothers (very low certainty).
An extended ZDV/3TC/LPV/r regimen administered to mothers showed no clear difference in HIV transmission at 6 months among those whose diagnostic testing… compared with short course ZDV (intrapartum ZDV/3TC/sdNVP) (low certainty).
An extended ZDV/3TC/LPV/r regimen administered to mothers may leads to lower HIV transmission at 12 months among those whose diagnostic testing… compared with short course ZDV (intrapartum ZDV/3TC/sdNVP) (low certainty).
An extended NVP regimen administered to infants for 14 weeks showed no clear difference in infant Mortality at 24 months among those uninfected at birth compared with sdNVP plus ZDV (1week) (moderate certainty).
An extended ZDV/3TC/LPV/r regimen administered to mothers showed no clear difference in infant Mortality at 6 months compared with short course ZDV (intrapartum ZDV/3TC/sdNVP) (low certainty).
An extended ZDV/3TC/LPV/r regimen administered to mothers showed no clear difference in infant Mortality at 12 months compared with short course ZDV (intrapartum ZDV/3TC/sdNVP) (low certainty).
An extended ZDV/3TC/LPV/r regimen administered to mothers showed no clear difference in HIV transmission or Death at 6 months among those whose HIV… compared with short course ZDV (intrapartum ZDV/3TC/sdNVP) (low certainty).
An extended ZDV/3TC/LPV/r regimen administered to mothers probably leads to lower HIV transmission or Death at 12 months among those whose HIV… compared with short course ZDV (intrapartum ZDV/3TC/sdNVP) (moderate certainty).